The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulf onamide

J Med Chem. 1994 Feb 4;37(3):329-31. doi: 10.1021/jm00029a001.

Authors

P D Stein¹, J T Hunt, D M Floyd, S Moreland, K E Dickinson, C Mitchell, E C Liu, M L Webb, N Murugesan, J Dickey, et al.

Affiliation

¹ Department of Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000.

PMID: 8308857
DOI: 10.1021/jm00029a001

No abstract available

MeSH terms

Animals
Antihypertensive Agents / chemical synthesis
Antihypertensive Agents / therapeutic use
Cell Line
Dansyl Compounds / chemical synthesis*
Dansyl Compounds / pharmacology
Dansyl Compounds / therapeutic use
Endothelin Receptor Antagonists*
Endothelins / metabolism
Hypertension / drug therapy
Molecular Structure
Muscle, Smooth, Vascular / drug effects
Muscle, Smooth, Vascular / metabolism
Rabbits
Rats
Structure-Activity Relationship

Substances

Antihypertensive Agents
Dansyl Compounds
Endothelin Receptor Antagonists
Endothelins
5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide